Cannabis stocks had a strong session Thursday thanks to a victory handed down by the Drug Enforcement Administration, and the sector continued those gains Friday, September 28.
The DEA announced that it has placed certain drug products that have been approved by the Food and Drug Administration that contain cannabidiol (CBD) in schedule V, which means the government believes the products have the lowest potential for abuse.
GW Pharmaceuticals PLC (GWPH) - Get Report will directly benefit from the new classification as it can now sell Epidiolex, a treatment for pediatric epilepsy that contains cannabidiol. GW Pharmaceuticals stock jumped nearly 7% on the news Thursday and was rising another 1.4% Friday.
The DEA has not rescheduled cannabidiol itself, however, just FDA-approved pharmaceutical products containing the cannabis extract.
Tilray Inc. (TLRY) - Get Report rose 5.5% premarket and shares of India Globalization Capital Inc. (IGC) - Get Report jumped another 21% premarket after also rising 52% in Thursday's session after announced that it entered into the CBD-infused energy drink business.
Want to Buy $1 Worth of Stock for 90 Cents or Less? You can with certain so-called "closed-end" mutual funds - an often overlooked investment class. Click here to register for a free online video in which TheStreet's retirement expert Robert Powell and an all-star panel tell you all you need to know. The webinar is sponsored by Nuveen.